| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 3,100.1 | 1,845 | 744.2 | 1,689.6 |
| Depreciation and amortization | 673.4 | 445.7 | 236.3 | 428.7 |
| Stock-based compensation expense | 94.8 | 57.9 | 26.6 | 79.9 |
| Deferred income tax benefit | -40.5 | -35.4 | -13.9 | -33.6 |
| Gain on bargain purchase acquisition | - | - | - | 0 |
| Net change in components of working capital | 435.2 | 374.3 | 271.3 | 197.6 |
| Net change in other long-term assets and liabilities | 259.9 | 242.8 | 43 | -0.6 |
| Net cash provided by operating activities | 3,652.5 | 2,181.7 | 764.9 | 1,967.6 |
| Capital expenditures | 742.9 | 485.7 | 188.6 | 465.6 |
| Proceeds from disposals of property, plant and equipment | 7.6 | 5.7 | 4.1 | 7.1 |
| Purchases of investments | 87.4 | 12.6 | 3.1 | 20.7 |
| Sales and maturities of investments | 16.3 | 11.6 | 7.2 | 181.7 |
| Acquisitions, net of cash acquired | 2,772.2 | 2,483.2 | 2,172.2 | 2,099.8 |
| Other, net | 0 | 0 | 0 | 0.9 |
| Net cash used in investing activities | -3,578.6 | -2,964.2 | -2,352.6 | -2,398.2 |
| Proceeds from issuance of senior notes and other long-term debt | 1,430 | 1,430 | - | 1,500.1 |
| Repayments of senior notes and other long-term debt | 401.3 | 400.9 | 400.5 | 353.7 |
| Borrowings (repayments) under commercial paper programs, net | 0 | 0 | 639.8 | 0 |
| Payment of costs related to debt financing | 29.1 | 9.1 | 0 | 14.7 |
| Payment of deferred purchase price related to acquisitions | - | - | - | 0 |
| Purchase of treasury stock | 493.9 | 341 | 180.9 | 520.4 |
| Proceeds from exercise of stock options | 445.4 | 333.8 | 53.2 | 320.3 |
| Distributions to and purchases of noncontrolling interests | 5.5 | 1.9 | - | 20.8 |
| Dividend payments | 600.3 | 399.1 | 199.5 | 396.2 |
| Other, net | 0.7 | 0.5 | -0.7 | 1.2 |
| Net cash provided by financing activities | 346 | 612.3 | -88.6 | 515.8 |
| Effect of exchange rate changes on cash and cash equivalents | 62.4 | 60.2 | 16.5 | 2.8 |
| Net increase in cash and cash equivalents | 482.3 | -110 | -1,659.8 | 88 |
| Cash and cash equivalents at beginning of period | 3,317 | 3,317 | 3,317 | 1,475 |
| Cash and cash equivalents at end of period | 3,799.3 | 3,207 | 1,657.2 | 1,563 |
AMPHENOL CORP DE (APH)
AMPHENOL CORP DE (APH)